SporTRIA study-a multicentre trial protocol for excretion kinetics of triamcinolone acetonide following sport-related intra-articular injections in knees: definitions of the washout periods

Edem Allado, Mathias Poussel, Nicolas Gambier, Véronique Saunier, Marjorie Starck, Corinne Buisson, Gael Cinquetti, Eliane Albuisson, Bruno Chenuel, Edem Allado, Mathias Poussel, Nicolas Gambier, Véronique Saunier, Marjorie Starck, Corinne Buisson, Gael Cinquetti, Eliane Albuisson, Bruno Chenuel

Abstract

Introduction: Intra-articular (IA) and peri-articular glucocorticoid (GC) injections are common in sports medicine. However, from 1 January 2022, all injectable GC routes (including IA administration) will be prohibited in-competition by World Anti-Doping Agency (WADA). Owing to these rules, an IA GC treatment out-of-competition could result in an adverse analytical finding in-competition if the washout period is not clearly defined. The aim of this study is to determine the urinary excretion profile of triamcinolone acetonide following IA injection to strengthen the definition of the washout periods.

Methods and analysis: This is a prospective multicentre trial to include 20 subjects who practice sports for at least 4 hours/week and present a knee disorder requiring IA injection of triamcinolone acetonide for therapeutic purposes. To determine the excretion profile of triamcinolone acetonide in both urine and blood following IA injection of the drug, We will perform 20 urinary tests and 20 dried blood spot tests, two prior to GC injection (baseline) and the last one at 35 days. Analyses will be performed by the French antidoping agency laboratory in accordance with WADA standards and regulations.

Ethics and dissemination: The study protocol was approved by the French ethics committee (CPP Sud Est III-Lyon-2020-070B on 06 October 2020). All subjects will provide written informed consent. The results of this study will be accessible in peer-reviewed publication and be presented at academic conference.

Trial registration number: NCT04574232.

Keywords: knee; rheumatology; sports medicine.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Allen M, Stuart MC, Gribble H, et al. . Needle-use declarations at the Olympic Games Rio 2016. Br J Sports Med 2018;52:747–52. 10.1136/bjsports-2017-098294
    1. Rochcongar P. L'utilisation et La prescription des corticoïdes en médecine Du sport. Sci Sports 2005;20:197–8. 10.1016/j.scispo.2005.01.025
    1. Collomp K, Arlettaz A, Buisson C, et al. . Glucocorticoid administration in athletes: performance, metabolism and detection. Steroids 2016;115:193–202. 10.1016/j.steroids.2016.09.008
    1. Vernec A, Slack A, Harcourt PR, et al. . Glucocorticoids in elite sport: current status, controversies and innovative management strategies-a narrative review. Br J Sports Med 2020;54:8–12. 10.1136/bjsports-2018-100196
    1. Brinks A, Koes BW, Volkers ACW, et al. . Adverse effects of extra-articular corticosteroid injections: a systematic review. BMC Musculoskelet Disord 2010;11:206. 10.1186/1471-2474-11-206
    1. Lavelle W, Lavelle ED, Lavelle L. Intra-Articular injections. Med Clin North Am 2007;91:241–50. 10.1016/j.mcna.2006.12.002
    1. World Anti-Doping Agency . 2021 Prohibited List - Summary of major modifications and explanatory notes 2021.
    1. World Anti-Doping Agency . List of prohibited substances and methods, 2021. Available:
    1. Duclos M. Glucocorticoids: a doping agent? Endocrinol Metab Clin North Am 2010;39:107–26. 10.1016/j.ecl.2009.10.001
    1. Collomp K, Arlettaz A, Portier H, et al. . Short-Term glucocorticoid intake combined with intense training on performance and hormonal responses. Br J Sports Med 2008;42:983–8. 10.1136/bjsm.2007.043083
    1. Kuipers H, Hullenaar GACV, Pluim BM, et al. . Four weeks’ corticosteroid inhalation does not augment maximal power output in endurance athletes. Br J Sports Med 2008;42:568–71. 10.1136/bjsm.2007.042572
    1. Baume N, Steel G, Edwards T, et al. . No variation of physical performance and perceived exertion after adrenal gland stimulation by synthetic ACTH (synacthen) in cyclists. Eur J Appl Physiol 2008;104:589–600. 10.1007/s00421-008-0802-y
    1. Le Panse B, Thomasson R, Jollin L, et al. . Short-Term glucocorticoid intake improves exercise endurance in healthy recreationally trained women. Eur J Appl Physiol 2009;107:437–43. 10.1007/s00421-009-1149-8
    1. Soetens E, De Meirleir K, Hueting JE. No influence of ACTH on maximal performance. Psychopharmacology 1995;118:260–6. 10.1007/BF02245953
    1. Chen T-T, Tseng Y-C, Huang T-Y, et al. . Elimination profile of triamcinolone in urine following oral administration. Drug Test Anal 2018;10:860–4. 10.1002/dta.2343
    1. Kaliszewski P, Kończak D, Chołbiński P, et al. . Budesonide treatment of professional athletes and anti-doping testing--case studies. Acta Pol Pharm 2016;73:229–37.
    1. Matabosch X, Pozo OJ, Pérez-Mañá C, et al. . Evaluation of the reporting level to detect triamcinolone acetonide misuse in sports. J Steroid Biochem Mol Biol 2015;145:94–102. 10.1016/j.jsbmb.2014.09.018
    1. Jones A, Regan M, Ledingham J, et al. . Importance of placement of intra-articular steroid injections. BMJ 1993;307:1329–30. 10.1136/bmj.307.6915.1329
    1. Coll S, Matabosch X, Llorente-Onaindia J, et al. . Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration. Drug Test Anal 2019;11:1589–600. 10.1002/dta.2614
    1. Coll S, Monfort N, Alechaga Élida, et al. . Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations. Steroids 2019;151:108464. 10.1016/j.steroids.2019.108464
    1. Chang C-W, Huang T-Y, Tseng Y-C, et al. . Positive doping results caused by the single-dose local injection of triamcinolone acetonide. Forensic Sci Int 2014;244:1–6. 10.1016/j.forsciint.2014.07.024
    1. Ventura R, Daley-Yates P, Mazzoni I, et al. . A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes. Br J Sports Med 2021;55:631–42. 10.1136/bjsports-2020-103512
    1. Fitch K. Glucocorticoids at the Olympic games: state-of-the-art review. Br J Sports Med 2016;50:1267.10.1136/bjsports-2016-096664
    1. Pigozzi F, Di Gianfrancesco A, Zorzoli M, et al. . Why glucocorticosteroids should remain in the list of prohibited substances: a sports medicine viewpoint. Int J Immunopathol Pharmacol 2012;25:19–24. 10.1177/039463201202500103
    1. World Anti-Doping Agency . Minimum required performance levels for detection and identification of non-threshold substances, 2019. Available:
    1. Pereira HMG, Sardela VF, Padilha MC, et al. . Doping control analysis at the Rio 2016 Olympic and Paralympic Games. Drug Test Anal 2017;9:1658–72. 10.1002/dta.2329
    1. Thevis M, Kuuranne T, Dib J, et al. . Do dried blood spots (DBS) have the potential to support result management processes in routine sports drug testing? Drug Test Anal 2020;12:704–10. 10.1002/dta.2790
    1. World Anti-Doping Agency . Technical directive dried blood spot (TDDBS), 2021. Available:
    1. Thomas A, Geyer H, Schänzer W, et al. . Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. Anal Bioanal Chem 2012;403:1279–89. 10.1007/s00216-011-5655-2
    1. Gaillard Y, Vayssette F, Pépin G. Compared interest between hair analysis and urinalysis in doping controls. Forensic Sci Int 2000;107:361–79. 10.1016/S0379-0738(99)00179-6
    1. Nussinovitch U, de Carvalho JF, Pereira RMR, et al. . Glucocorticoids and the cardiovascular system: state of the art. Curr Pharm Des 2010;16:3574–85. 10.2174/138161210793797870
    1. Schakman O, Gilson H, Kalista S, et al. . Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res 2009;72 Suppl 1:36–41. 10.1159/000229762
    1. Compston J. Glucocorticoid-Induced osteoporosis: an update. Endocrine 2018;61:7–16. 10.1007/s12020-018-1588-2

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner